Mapping interactions of gastric inhibitory polypeptide with GIPR N-terminus using NMR and molecular dynamics simulations

Journal of Peptide Science

Volumn 16, Issue 8, 2010, Pages 383-391

  Tikhele, Sonali H ^a   Pissurlenkar, Raghuvir R S ^a   Srivastava, Sudha ^b   Saran, Anil ^a   Coutinho, Evans C ^a  

^a BOMBAY COLLEGE OF PHARMACY   (India)

^b TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

Author keywords

2D NMR; Diabetes; G protein coupled receptor (GPCR); GIP receptor (GIPR); Glucose dependent insulinotropic polypeptide; MD simulations

Indexed keywords

ASPARAGINE; ASPARTIC ACID; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUTAMINE; HORMONE RECEPTOR; SERINE; UNCLASSIFIED DRUG; WATER;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HORMONE RECEPTOR INTERACTION; INSULIN LIKE ACTIVITY; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE; NUCLEAR OVERHAUSER EFFECT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SIMULATION; CHEMISTRY; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE;

GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR DYNAMICS SIMULATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 77957324131     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1250     Document Type: Article

References (38)

1. Jornvall H, Carlquist M, Kwauk S, Otte SC, McIntosh CH, Brown JC, Mutt V. Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP). FEBS Lett. 1981; 123: 205-210. (Pubitemid 11148752)
2. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: the neglected incretin revisited. Regul. Pept. 2002; 107: 1-13.
3. Lu M, Wheeler MB, Leng XH, Boyd AE, 3rd. The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37). Endocrinology 1993; 132: 94-100.
4. Gault VA, O'Harte FP, Harriott P, Mooney MH, Green BD, Flatt PR. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia 2003; 46: 222-230.
5. Eckel RH, Fujimoto WY, Brunzell JD. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 1979; 28: 1141-1142. (Pubitemid 10215022)
6. Raben A, Andersen HB, Christensen NJ, Madsen J, Holst JJ, Astrup A. Evidence for an abnormal postprandial response toa high-fat meal in women predisposed to obesity. Am. J. Physiol. 1994; 267: E549-E559.
7. Wasada T. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J.Clin. Invest. 1981;68:1106-1107.
8. Yip RGC, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. Endocrinology 1998; 139: 4004-4007.
9. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 2000; 85: 3575-3581.
10. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993; 214: 829-835.
11. 2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes 1999; 48: 758-765.
12. Malde AK, Srivastava SS, Coutinho EC. Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modeling. J. Pept. Sci. 2007; 13: 287-300.
13. Alana I, Malthouse JP, O'Harte FP, Hewage CM. The bioactive conformation of glucose-dependent insulinotropic polypeptide by NMR and CD spectroscopy. Proteins 2007; 68: 92-99.
14. Alana I, Parker JC, Gault VA, Flatt PR, O'Harte FP, Malthouse JP, Hewage CM. NMR and alanine scan studies of glucose-dependent insulinotropic polypeptide in water. J. Biol. Chem. 2006; 281: 16370-16376.
15. Parthier C, Kleinschmidt M, Neumann P, Rudolph R, Manhart S, Schlenzig D, Fanghanel J, Rahfeld JU, Demuth HU, Stubbs MT. Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 13942-13947.
16. Derome A, Williamson M. 2D homonuclear shift correlation phase sensitive using TPPI with double quantum filter phase cycle. J. Magn. Reson. 1990; 88: 177-185.
17. Kumar A, Ernst RR, Wüthrich K. A two-dimensional nuclear Overhauser enhancement (2D NOE) experiment for the elucidation of complete proton - proton cross-relaxation networks in biological macromolecules. Biochem. Biophys. Res. Commun. 1980; 95: 1-6.
18. Bax A, Davis DG. MLEV-17 based two-dimensional homonuclear magnetization transfer spectroscopy. J. Magn. Reson. 1985; 65: 355-360.
19. Hwang TL, Shaka AJ. Water suppression that works. Excitation sculpting using arbitrary waveforms and pulsed field gradients. J. Magn. Reson. 1995; 112: 275-279.
20. Wüthrich K. NMR of Proteins and Nucleic Acids. John Wiley & Sons: New York, 1986.
21. Vuister GW, Bax A. Quantitative J correlation: a new approach for measuring homonuclear three-bond J(HNH.alpha.) coupling constants in 15N-enriched proteins. J. Am. Chem. Soc. 1993; 115: 7772-7777.
22. Insight-II. Accelrys Inc.: San Diego, CA, USA, 2005.
23. Maple JR, Dinur U, Hagler AT. Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces. Proc. Natl. Acad. Sci. U.S.A. 1988; 85: 5350-5354.
24. Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, Gregersen BA, Klepeis JL, Kolossvary I, Moraes MA, Sacerdoti FD, Salmon JK, Shan Y, Shaw DE. In Supercomputing, 2006. SC'06. Proceedings of the ACM/IEEE SC 2006 Conference, 2006, Tampa, FL, 2006; 43.
25. Berendsen HJC, Postma JPM, Gunsteren WFv, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984; 81: 3684-3690.
26. Ryckaert J-P, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of asystem with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977; 23: 327-341.
27. Wüthrich K, Billeter M, Braun W. Polypeptide secondary structure determination by nuclear magnetic resonance observation of short proton - proton distances. J. Mol. Biol. 1984; 180: 715-740.
28. Wishart DS, Sykes BD, Richards FM. Chemical shift index: a fast and simple method for the assignment of protein secondary structure through NMR spectroscopy. Biochemistry 1992; 31: 1647-1651.
29. Wishart DS, Sykes BD. The 13C chemical-shift index: a simple method for the identification of protein secondary structure using 13C chemical-shift data. J. Biomol. NMR 1994; 4: 171-180.
30. Bach AC, Eyermann CJ, Gross JD, Bower MJ, Harlow RL, Weber PC, DeGrado WF. Structural studies of a family of high affinity ligands for GPIIb/IIIa. J. Am. Chem. Soc. 1994; 116: 3207-3219.
31. Marx UC, Adermann K, Bayer P, Forssmann WG, Rosch P. Solution structures of human parathyroid hormone fragments hPTH(1-34) and hPTH(1-39) and bovine parathyroid hormone fragment bPTH(1-37). Biochem. Biophys. Res. Commun. 2000; 267: 213-220.
32. Thornton K, Gorenstein DG. Structure of glucagon-like peptide (7-36) amide in a dodecylphosphocholine micelle as determined by 2D NMR. Biochemistry 1994; 33: 3532-3539.
33. Neidigh JW, Fesinmeyer RM, Prickett KS, Andersen NH. Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. Biochemistry 2001; 40: 13188-13200.
34. Sun C, Song D, Davis-Taber RA, Barrett LW, Scott VE, Richardson PL, Pereda-Lopez A, Uchic ME, Solomon LR, Lake MR, Walter KA, Hajduk PJ, Olejniczak ET. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. Proc. Natl. Acad. Sci. U.S.A. 2007; 104: 7875-7880.
35. Georgios AS, Spyridon P, George P, Paul C. Monitoring the structural consequences of Phe122→D-Phe192 and Leu15→Aib substitution in human/rat corticotropin releasing hormone. Implications for design of CRH antagonists. Eur. J. Biochem. 2002; 269: 6009-6019.
36. Sasaki K, Dockerill S, Adamiak DA, Tickle IJ, Blundell T. X-ray analysis of glucagon and its relationship to receptor binding. Nature 1975; 257: 751-757.
37. Jin L, Briggs SL, Chandrasekhar S, Chirgadze NY, Clawson DK, Schevitz RW, Smiley DL, Tashjian AH, Zhang F. Crystal structure of human parathyroid hormone 1-34 at 0.9-Å resolution. J. Biol. Chem. 2000; 275: 27238-27244.
38. Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT. Passing the baton in class B GPCRs: peptide hormone activation via helix induction?. Trends Biochem. Sci. 2009; 34: 303-310.